Nikolay V Zyk
Overview
Explore the profile of Nikolay V Zyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasnovskaya O, Akasov R, Spector D, Pavlov K, Bubley A, Kuzmin V, et al.
ACS Appl Mater Interfaces
. 2023 Feb;
15(10):12882-12894.
PMID: 36854172
Controlled photoreduction of Pt(IV) prodrugs is a challenging task due to the possibility of targeted light-controlled activation of anticancer agents without affecting healthy tissues. Also, a conjugation of photosensitizers and...
2.
Machulkin A, Nimenko E, Zyk N, Uspenskaia A, Smirnova G, Khan I, et al.
Molecules
. 2022 Dec;
27(24).
PMID: 36557929
Prostate cancer is the second most common type of cancer among men. The main method of its treatment is androgen deprivation therapy, which has a wide range of side effects....
3.
Spector D, Erofeev A, Gorelkin P, Vaneev A, Akasov R, Ulyanovskiy N, et al.
Inorg Chem
. 2022 Sep;
61(37):14705-14717.
PMID: 36047922
We report herein a Pt(IV) prodrug with metronidazole in axial positions -. The nitroaromatic axial ligand was conjugated with a cisplatin scaffold to irreversibly reduce under hypoxic conditions, thereby retaining...
4.
Spector D, Pavlov K, Akasov R, Vaneev A, Erofeev A, Gorelkin P, et al.
J Med Chem
. 2022 Jun;
65(12):8227-8244.
PMID: 35675651
We report herein the design, synthesis, and biological investigation of a series of novel Pt(IV) prodrugs with non-steroidal anti-inflammatory drugs naproxen, diclofenac, and flurbiprofen, as well as these with stearic...
5.
Finko A, Sokolov A, Guk D, Tafeenko V, Moiseeva A, Skvortsov D, et al.
RSC Adv
. 2022 Apr;
12(12):7133-7148.
PMID: 35424664
A series of new organic ligands (5,5')-2,2'-(alkane-α,ω-diyldiselenyl)-bis-5-(2-pyridylmethylene)-3,5-dihydro-4-imidazol-4-ones (L) consisting of two 5-(2-pyridylmethylene)-3,5-dihydro-4-imidazol-4-one units linked with polymethylene chains of various lengths ( = 2-10, where is the number of CH units)...
6.
Machulkin A, Uspenskaya A, Zyk N, Nimenko E, Ber A, Petrov S, et al.
J Med Chem
. 2021 Nov;
64(23):17123-17145.
PMID: 34797052
Prostate cancer is the second most common type of cancer among men. Its main method of treatment is chemotherapy, which has a wide range of side effects. One of the...
7.
Machulkin A, Uspenskaya A, Zyk N, Nimenko E, Ber A, Petrov S, et al.
Eur J Med Chem
. 2021 Oct;
227:113936.
PMID: 34717125
Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of the leading causes of cancer death. The development of approaches to the treatment of this...
8.
Filatov V, Kuznetsova J, Petrovskaya L, Yuzabchuk D, Tafeenko V, Zyk N, et al.
ACS Omega
. 2021 Sep;
6(35):22740-22751.
PMID: 34514245
A convenient and versatile one-pot method for synthesis of 1,3-bis-aryl spirooxindolo-β-lactams from isatin Schiff bases and substituted phenylacetic acids using ketene-imine cycloaddition reaction with TsCl for a ketene generation has...
9.
Machulkin A, Shafikov R, Uspenskaya A, Petrov S, Ber A, Skvortsov D, et al.
J Med Chem
. 2021 Apr;
64(8):4532-4552.
PMID: 33822606
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a suitable target for specific delivery of antitumor drugs and diagnostic agents due to its overexpression in prostate...
10.
Petrov S, Machulkin A, Uspenskaya A, Zyk N, Nimenko E, Garanina A, et al.
Molecules
. 2020 Dec;
25(24).
PMID: 33302417
A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) receptor was developed. The proposed platform contains...